Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00075374 · ClinicalTrials.gov registry record · Phase 2

Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer

A Phase 2 study, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
Phase 2
Development phase
6
Enrollment target

NCT00075374 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 6 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00075374, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
6 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which docetaxel regimen is more effective for non-small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of two regimens of docetaxel in treating patients who have not previously received chemotherapy for unresectable stage IIIB or stage IV non-small cell lung cancer.

Interventions

  • DRUG docetaxel

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2003-10
Est. Completion 2005-04
Phase Phase 2

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT00075374

The ClinicalTrials.gov registry entry for NCT00075374 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which docetaxel is the first listed.

NCT00075374 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00075374 about?

NCT00075374 is a clinical study titled "Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which docetaxel regimen is more effective for non-small cell lung cancer. PURPOSE: Randomized phase II trial to compare the effectiveness o...

What is the current status of trial NCT00075374?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2003-10. Estimated completion is 2005-04.

What interventions are being tested in trial NCT00075374?

The interventions under investigation include: docetaxel (DRUG).

Who is sponsoring clinical trial NCT00075374?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.